Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Completed

• Conditions: Atrial Fibrillation

• Registration Number: NCT01721837
• Lead Sponsor: Boehringer Ingelheim

Brief Summary

Non-interventional, observational study of physicians' use of Dabigatran etexilate for stroke prevention in patients with atrial fibrillation and mild to moderate renal impairment

Detailed Description

Not available

Study Timeline

• Study Start: 2012-10
• Study First Submitted: 2012-11-02
• Study First Submitted QC: 2012-11-02
• Study First Posted: 2012-11-06
• Primary Completion: 2013-06
• Study Completion: 2013-06
• Status Verified: 2014-06
• Results First Submitted: 2014-06-30
• Results First Submitted QC: 2014-06-30
• Last Update Submitted: 2014-06-30
• Results First Posted: 2014-07-31
• Last Update Posted: 2014-07-31

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 4340

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Creatinine Clearance (Recalculated Using Entries of Age, Gender, Body Weight and Serum Creatinine Made by the Physician)	One single observation time point: at the time of prescription before the first intake of dabigatran etexilate	The creatinine clearance was recalculated with the Cockcroft-Gault formula using age, gender, body weight, and serum creatinine.

Trial Locations

Locations (1616)

Boehringer Ingelheim Investigational Site 626; 🇩🇪 Aachen, Germany

Boehringer Ingelheim Investigational Site 627; 🇩🇪 Aachen, Germany

Boehringer Ingelheim Investigational Site 642; 🇩🇪 Aachen, Germany

Boehringer Ingelheim Investigational Site 643; 🇩🇪 Aachen, Germany

Boehringer Ingelheim Investigational Site 156; 🇩🇪 Aalen, Germany

Boehringer Ingelheim Investigational Site 159; 🇩🇪 Aalen, Germany

Boehringer Ingelheim Investigational Site 472; 🇩🇪 Aarbergen, Germany

Boehringer Ingelheim Investigational Site 842; 🇩🇪 Ahaus-Alstaette, Germany

Boehringer Ingelheim Investigational Site 830; 🇩🇪 Ahaus, Germany

Boehringer Ingelheim Investigational Site 834; 🇩🇪 Ahaus, Germany

Scroll for more (1606 remaining)